Annual report pursuant to Section 13 and 15(d)

SEGMENT INFORMATION

v3.23.4
SEGMENT INFORMATION
 12 Months Ended
Oct. 31, 2023
Segment Reporting [Abstract]  
SEGMENT INFORMATION

8. SEGMENT INFORMATION

 

We follow the accounting guidance of ASC 280, Segment Reporting (“ASC 280”). Reportable operating segments are determined based on the management approach. The management approach, as defined by ASC 280, is based on the way that the chief operating decision-maker organizes the segments within an enterprise for making operating decisions and assessing performance. While our results of operations are primarily reviewed on a consolidated basis, the chief operating decision-maker manages the enterprise in four reportable segments, each with different operating and potential revenue generating characteristics: (i) CAR-T Therapeutics, (ii) Cancer Vaccines, (iii) Anti-Viral Therapeutics and (iv) Other. The following represents selected financial information for our segments for the years ended October 31, 2023 and 2022:

 

             
    Year Ended October 31,  
    2023     2022  
Net income (loss):                
CAR-T Therapeutics   $ (3,879 )   $ (5,776 )
Cancer Vaccines     (5,111 )     (4,889 )
Anti-Viral Therapeutics     (945 )     (3,075 )
Other     5       (31 )
Total   $ (9,930 )   $ (13,771 )
                 
Total operating costs and expenses   $ 11,221     $ 13,875  
Less non-cash share-based compensation     (4,735 )     (6,655 )
Operating costs and expenses excluding non-cash share-based compensation   $ 6,486     $ 7,220  
                 
Operating costs and expenses excluding non-cash share based compensation:                
CAR-T Therapeutics   $ 2,467     $ 3,206  
Cancer Vaccines     3,265       2,355  
Anti-Viral Therapeutics     553       1,634  
Other     201       25  
Total   $ 6,486     $ 7,220  

 

                 
      October 31,  
      2023       2022  
Total assets:                
CAR-T Therapeutics   $ 7,523     $ 16,921  
Cancer Vaccines     17,215       9,442  
Anti-Viral Therapeutics     700       3,811  
Other     84       238  
Total   $ 25,522     $ 30,412  

 

Operating costs and expenses excluding non-cash share-based compensation is the measurement the chief operating decision-maker uses in managing the enterprise.

 

The Company’s consolidated revenue of $210,000 and inventor royalties, contingent legal fees, litigation and licensing expense of $161,000, for the year ended October 31, 2023 were solely related to our other segment. All our revenue is generated domestically (United States) based on the country in which the licensee is located.